5 - Year: 2.409
Ranking & Category
- 167th of 261 in Pharmacology & Pharmacy
Aims & Scope
Current Drug Delivery aims to publish peer-reviewed articles, research articles, in-depth reviews/mini-reviews, and drug clinical trials studies in the rapidly developing field of drug delivery. Modern drug research aims to build delivery properties of a drug at the design phase, however in many cases this idea cannot be met and the development of delivery systems becomes as important as the development of the drugs themselves.
The journal aims to cover the latest outstanding developments in drug and vaccine delivery employing physical, physico-chemical and chemical methods. The drugs include a wide range of bioactive compounds from simple pharmaceuticals to peptides, proteins, nucleotides, nucleosides and sugars. The journal will also report progress in the fields of transport routes and mechanisms including efflux proteins and multi-drug resistance.
The journal is essential for all pharmaceutical scientists involved in drug design, development and delivery.
BIOSIS Previews, BIOSIS Reviews Reports and Meetings, British Library, Cambridge Scientific Abstracts (CSA)/ProQuest, Chemical Abstracts Service/SciFinder, ChemWeb, CNKI Scholar, Dimensions, EBSCO, EMBASE, Genamics JournalSeek, Google Scholar, InCites, Index Copernicus, J-Gate, JournalTOCs, MediaFinder®-Standard Periodical Directory, MEDLINE/PubMed/Index Medicus, Open Abstracts (I4OA), Norwegian Register, PubsHub, QOAM, Science Citation Index Expanded™ (SciSearch®), Scilit, Scopus, Suweco CZ, TOC Premier, and Ulrich's Periodicals Directory.
Current Drug Delivery was launched in 2004. Dr. Deng-Guang Yu serves as the Editor-in-Chief of the journal.
"For many drugs, delivery is as big a challenge as development. Current Drug Delivery provides essential information for all drug scientists."
Jhon de Jersey
The Univ. of Queensland, Australia
I would like to thank the entire editing team of the Current Drug Delivery for their commitment to resolve all issues regarding the publication of my article. All sectors work in consonance and are quite agile.
I believe that my work is of interest both in the pharmaceutical industry and in the biotechnology industry, since once the bioavailability of the active substance is guaranteed at its site of action, the better is the result for the patient. And so it is in the interest of the whole chain of health goods production, to encourage them to study this issue of biopharmaceutical stability in depth.
At the moment I am working with ophthalmic release systems, which is still in progress. I look forward to future contributions to your journal.
Aline Gravinez Perissinato
(LACFAR, Institute of Chemistry, Federal University of Alfenas, Alfenas, Brazil.)
Has contributed: Simple Strategy to Protect Lactase Activity in Solid Formulation.